Cargando…

DNA Methylation Signatures Predicting Bevacizumab Efficacy in Metastatic Breast Cancer

Background: Biomarkers predicting response to bevacizumab in breast cancer are still missing. Since epigenetic modifications can contribute to an aberrant regulation of angiogenesis and treatment resistance, we investigated the influence of DNA methylation patterns on bevacizumab efficacy. Methods:...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gampenrieder, Simon Peter, Rinnerthaler, Gabriel, Hackl, Hubert, Pulverer, Walter, Weinhaeusel, Andreas, Ilic, Suzana, Hufnagl, Clemens, Hauser-Kronberger, Cornelia, Egle, Alexander, Risch, Angela, Greil, Richard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2018
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5928889/ https://www.ncbi.nlm.nih.gov/pubmed/29721079 http://dx.doi.org/10.7150/thno.23544

Ejemplares similares

Low Expression of miR-20a-5p Predicts Benefit to Bevacizumab in Metastatic Breast Cancer Patients Treated within the TANIA Phase III Trial
por: Rinnerthaler, Gabriel, et al.
Publicado: (2020)

miR-16-5p Is a Stably-Expressed Housekeeping MicroRNA in Breast Cancer Tissues from Primary Tumors and from Metastatic Sites
por: Rinnerthaler, Gabriel, et al.
Publicado: (2016)

Overcoming negative predictions of microRNA expressions to gemcitabine response with FOLFIRINOX in advanced pancreatic cancer patients
por: Schlick, Konstantin, et al.
Publicado: (2020)

ASCO 2018 highlights: metastatic breast cancer
por: Rinnerthaler, Gabriel, et al.
Publicado: (2018)

SABCS 2016: systemic therapy for metastatic breast cancer
por: Gampenrieder, Simon Peter, et al.
Publicado: (2017)

Cure in metastatic breast cancer
por: Westphal, Theresa, et al.
Publicado: (2018)

Capecitabine in combination with bendamustine in pretreated women with HER2-negative metastatic breast cancer: results of a phase II trial (AGMT MBC-6)
por: Rinnerthaler, Gabriel, et al.
Publicado: (2021)

Treatment Landscape for Patients with HER2-Positive Metastatic Breast Cancer: A Review on Emerging Treatment Options
por: Gampenrieder, Simon Peter, et al.
Publicado: (2020)

Impact of antibiotic treatment on immune-checkpoint blockade efficacy in advanced non-squamous non-small cell lung cancer
por: Huemer, Florian, et al.
Publicado: (2018)

Neoadjuvant Chemotherapy and Targeted Therapy in Breast Cancer: Past, Present, and Future
por: Gampenrieder, Simon P., et al.
Publicado: (2013)

CDK4/6 inhibition in luminal breast cancer
por: Gampenrieder, Simon Peter, et al.
Publicado: (2016)

HER2 Directed Antibody-Drug-Conjugates beyond T-DM1 in Breast Cancer
por: Rinnerthaler, Gabriel, et al.
Publicado: (2019)

SABCS 2017: lifestyle factors, hormone receptor-positive advanced disease, liquid biopsies, and prognosis
por: Rinnerthaler, Gabriel, et al.
Publicado: (2018)

Clonal evolution in relapsed and refractory diffuse large B-cell lymphoma is characterized by high dynamics of subclones
por: Melchardt, Thomas, et al.
Publicado: (2016)

Baseline Absolute Lymphocyte Count and ECOG Performance Score Are Associated with Survival in Advanced Non-Small Cell Lung Cancer Undergoing PD-1/PD-L1 Blockade
por: Huemer, Florian, et al.
Publicado: (2019)

Hospitalizations and Clinical Outcome in Metastatic Colorectal Cancer During Regorafenib or TAS-102 Therapy
por: Huemer, Florian, et al.
Publicado: (2020)

Correction: The influence of FCGR2A and FCGR3A polymorphisms on the survival of patients with recurrent or metastatic squamous cell head and neck cancer treated with cetuximab
por: Magnes, T., et al.
Publicado: (2019)

Updated Austrian treatment algorithm in HER2+ metastatic breast cancer
por: Bartsch, Rupert, et al.
Publicado: (2022)

Landscape of HER2-low metastatic breast cancer (MBC): results from the Austrian AGMT_MBC-Registry
por: Gampenrieder, Simon Peter, et al.
Publicado: (2021)

Radiologic complete response (rCR) in contrast-enhanced magnetic resonance imaging (CE-MRI) after neoadjuvant chemotherapy for early breast cancer predicts recurrence-free survival but not pathologic complete response (pCR)
por: Gampenrieder, Simon Peter, et al.
Publicado: (2019)

Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC - an analysis of the KRAS registry of the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie)
por: Huemer, Florian, et al.
Publicado: (2018)

Prognostic score in patients with recurrent or metastatic carcinoma of the head and neck treated with cetuximab and chemotherapy
por: Magnes, Teresa, et al.
Publicado: (2017)

Postoperative chemoradiotherapy with cisplatin is superior to radioimmunotherapy with cetuximab and radiotherapy alone: Analysis of the Austrian head and neck cancer registry of the AGMT
por: Magnes, Teresa, et al.
Publicado: (2021)

Association between antibiotics use and outcome in patients with NSCLC treated with immunotherapeutics
por: Huemer, F, et al.
Publicado: (2019)

Liver toxicity during temozolomide chemotherapy caused by Chinese herbs
por: Melchardt, Thomas, et al.
Publicado: (2014)

Ixazomib in combination with carboplatin in pretreated women with advanced triple-negative breast cancer, a phase I/II trial of the AGMT (AGMT MBC-10 trial)
por: Rinnerthaler, Gabriel, et al.
Publicado: (2018)

Austrian treatment algorithms in HER2-positive metastatic breast cancer: a 2022 update
por: Rinnerthaler, Gabriel, et al.
Publicado: (2022)

Chordoma Characterization of Significant Changes of the DNA Methylation Pattern
por: Rinner, Beate, et al.
Publicado: (2013)

Influence of body mass index on survival in indolent and mantle cell lymphomas: analysis of the StiL NHL1 trial
por: Weiss, Lukas, et al.
Publicado: (2017)

Intermittent low-dose bevacizumab in hereditary hemorrhagic telangiectasia: A case report
por: Huemer, Florian, et al.
Publicado: (2016)

Nonmetastatic pancreatic cancer: Improved survival with chemoradiotherapy > 40 Gy after systemic treatment
por: Bachmayer, Sebastian, et al.
Publicado: (2018)

Bevacizumab Combined with Chemotherapy Improves Survival for Patients with Metastatic Colorectal Cancer: Evidence from Meta Analysis
por: Ilic, Irena, et al.
Publicado: (2016)

Innovative methods for the identification of predictive biomarker signatures in oncology: Application to bevacizumab
por: Delmar, Paul, et al.
Publicado: (2017)

Comparison of high tone therapy and transcutaneous electrical nerve stimulation therapy in chemotherapy-induced polyneuropathy
por: Schaffler-Schaden, Dagmar, et al.
Publicado: (2020)

Antiangiogenic therapy in breast cancer
por: Gampenrieder, Simon Peter, et al.
Publicado: (2017)

Supervised versus autonomous exercise training in breast cancer patients: A multicenter randomized clinical trial
por: Westphal, Theresa, et al.
Publicado: (2018)

Analysis and Visualization Tool for Targeted Amplicon Bisulfite Sequencing on Ion Torrent Sequencers
por: Pabinger, Stephan, et al.
Publicado: (2016)

CYP39A1 polymorphism is associated with toxicity during intensive induction chemotherapy in patients with advanced head and neck cancer
por: Melchardt, Thomas, et al.
Publicado: (2015)

Management of metastatic colorectal cancer in patients ≥70 years - a single center experience
por: Huemer, Florian, et al.
Publicado: (2023)

Results of a hospitalization policy of asymptomatic and pre-symptomatic COVID-19-positive long-term care facility residents in the province of Salzburg—a report from the AGMT COVID-19 Registry
por: Huemer, Florian, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_uh1nke513ev8qh4oh2jc1g0q70